Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Februar 2023 12:16 ET | Quelle: Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING...
02. Juni 2021 09:35 ET | Quelle: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal modelsDue to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit...
12. Mai 2021 09:35 ET | Quelle: Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS

EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve...